AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 56(5), 1997, pp. 533-537
Copyright © 1997 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tacket, C. O.
Right arrow Articles by Levine, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tacket, C. O.
Right arrow Articles by Levine, M. M.

Volunteer Studies Investigating the Safety and Efficacy of Live Oral El Tor Vibrio cholerae O1 Vaccine Strain CVD 111

Carol O. Tacket, Karen L. Kotloff, Genevieve Losonsky, James P. Nataro, Jane Michalski, James B. Kaper, Robert Edelman AND Myron M. Levine
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland

A live oral cholera vaccine should ideally protect against both classical and El Tor biotypes of Vibrio cholerae O1. An El Tor biotype vaccine strain, therefore, would complement classical cholera vaccine strain CVD 103-HgR, a strain already in use in some countries. In this study, 25 healthy adult volunteers received a single dose of 108 colony-forming units of El Tor vaccine strain CVD 111, a derivative of El Tor Ogawa strain N16117 deleted in the virulence cassette. Three (12%) volunteers developed mild diarrhea (mean stool volume = 813 ml) but no systemic symptoms; 23 (92%) of the 25 volunteers developed serum vibriocidal antibodies (geometric mean titer = 1: 2,291). Five weeks after vaccination, 18 vaccinees and eight unimmunized control volunteers underwent wild-type challenge with El Tor Ogawa strain 3008. Three (16.7%) of 18 vaccinees and seven (87.5%) of eight controls developed diarrhea (P = 0.001) (vaccine efficacy = 80.9%). Further studies are underway to determine a dosage of CVD 111 that will be more clinically acceptable but equally immunogenic and protective.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
D. E. Cameron, J. M. Urbach, and J. J. Mekalanos
A defined transposon mutant library and its use in identifying motility genes in Vibrio cholerae
PNAS, June 24, 2008; 105(25): 8736 - 8741.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. S. Yoon and J. J. Mekalanos
Decreased Potency of the Vibrio cholerae Sheathed Flagellum To Trigger Host Innate Immunity
Infect. Immun., March 1, 2008; 76(3): 1282 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
V. Olivier, G. K. Haines III, Y. Tan, and K. J. F. Satchell
Hemolysin and the Multifunctional Autoprocessing RTX Toxin Are Virulence Factors during Intestinal Infection of Mice with Vibrio cholerae El Tor O1 Strains
Infect. Immun., October 1, 2007; 75(10): 5035 - 5042.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
V. Olivier, N. H. Salzman, and K. J. F. Satchell
Prolonged Colonization of Mice by Vibrio cholerae El Tor O1 Depends on Accessory Toxins
Infect. Immun., October 1, 2007; 75(10): 5043 - 5051.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Society of Tropical Medicine and Hygiene.